Grant: Strategic Projects - Group
University of Alberta
$255,989.00
Ligand guided polymeric nano-carriers for targeted vaccine and drug delivery in cancer
FY 2006-07
Summary
Cancer is expected to become the number one cause of death in Canada within the next five years. During the past few decades, the puzzle on many molecular and cellular processes involved in cancer has been elucidated, but establishment of effective therapies for the eradication of cancer has lagged behind. Chemotherapy is still the treatment of choice for most advanced cancers. However, it is rarely curative and mostly becomes ineffective by drug resistance. Moreover, emergence of intolerable toxicities by chemotherapeutic agents lowers the quality of life, significantly, in cancer patients. Immunotherapy is the more recent and unconventional form therapy for cancer, which is also rarely curative. Recent research has provided a strong case for the potential benefit of combined immuno and chemotherapy in the eradication of cancer. The objective of this proposal is to design smart vaccine and drug delivery systems that can enhance the efficacy and reduce the toxicity of immuno and chemotherapy in cancer patients and eventually lead to the eradication of this growing disease. In this context, smart biomaterials guided by specific ligands for targeted anticancer drug delivery to cancer cells and enhanced antigen delivery to dendritic cells will be developed.
Program
Strategic Projects - Group
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
336986-2006
Name nom
Samuel, John
Department département
Pharmacy/Pharmaceutical Science, Faculty of
Organization id
9
Institution établissement
University of Alberta
Province en
Alberta
Province fr
Alberta
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2006
Competition year année de concours
2006
Award amount
255989
Program id
STPGP
Program name en
Strategic Projects - Group
Program name fr
Projets stratégiques - De groupe
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1042
Committee name en
Strategic Projects Selection Panel - Biomedical Technologies
Committee name fr
Comité de sélection des projets stratégiques - Technologies biomédicales
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
3
Application title
Ligand guided polymeric nano-carriers for targeted vaccine and drug delivery in cancer
Keyword
NA
Application summary
Cancer is expected to become the number one cause of death in Canada within the next five years. During the past few decades, the puzzle on many molecular and cellular processes involved in cancer has been elucidated, but establishment of effective therapies for the eradication of cancer has lagged behind. Chemotherapy is still the treatment of choice for most advanced cancers. However, it is rarely curative and mostly becomes ineffective by drug resistance. Moreover, emergence of intolerable toxicities by chemotherapeutic agents lowers the quality of life, significantly, in cancer patients. Immunotherapy is the more recent and unconventional form therapy for cancer, which is also rarely curative. Recent research has provided a strong case for the potential benefit of combined immuno and chemotherapy in the eradication of cancer. The objective of this proposal is to design smart vaccine and drug delivery systems that can enhance the efficacy and reduce the toxicity of immuno and chemotherapy in cancer patients and eventually lead to the eradication of this growing disease. In this context, smart biomaterials guided by specific ligands for targeted anticancer drug delivery to cancer cells and enhanced antigen delivery to dendritic cells will be developed.